ARON 3D_Transparent

Urothelial Carcinoma

Bone metastases ARON 2EV

Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project

Rizzo A, et al
Clin Exp Med
2025
Time to metastasis

Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study

Pichler R, et al
Clin Exp Metastasis
2025
PIS

Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset

Rizzo A, et al
Clin Exp Metastasis
2025
Geo diff

Geographical Differences in the Management and Outcomes of PatientsWith Advanced Urothelial Carcinoma Treated With Pembrolizumab AfterProgression on Platinum-Based Chemotherapy: Results From ARON-2Study

Rizzo M,
JCO Glob Oncol.
2025
Concomitant Med ARON 2

Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study

Fiala O
et al. Clin Exp Metastasis
2025
Sequences ARON 2

Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Rizzo M
et al. Cancer Med
2025

Do you want to join us ?

Join us today
ARON 3D_Transparent
Youtube Linkedin

Coordinated and designed by Atteggiamento Digitale .

Legal and Privacy.